Methods for detection of prostate cancer, related biomarkers and kits for determining the biomarkers
AssigneeOy Arctic Partners Ab
InventorsKamlesh GIDWANI, Henna KEKKI, Kim PETTERSSON
Life of this patent
Estimating the term…
Abstract
The invention relates to non-invasive detection of prostate cancer on the basis of altered glycosylation patterns, and to biomarkers for use in the detection and to kits including reagents for determining levels of the biomarkers in biological samples.
Claims17
A glycan structure comprised on a carbohydrate antigen 19-9 (CA19-9) bearing molecular entity and capable of specific binding to Mannose binding lectin (MBL) as a biomarker for prostate cancer.
A method of determining prostate cancer disease state in a subject, the method comprising:
- a) assaying a sample obtained from said subject for the level of a CA19-9-bearing entity comprising a glycan structure capable of specific binding to MBL
- b) comparing the assayed level obtained in step a) with that of a control sample or a predetermined threshold value, and
- c) determining the prostate cancer disease state on the basis of said comparison.
A kit for use in determining prostate cancer disease state in a subject, comprising:
- a CA19-9-binding agent and a binder molecule specific for a glycan structure capable of specific binding to MBL, wherein either said CA19-9-binding agent or said binder molecule comprises a detectable label.
-32. (canceled)
Dependencies are inferred from the claim text.